A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT06012812 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Atopic Dermatitis

Interventions

DRUG: SHR-1819 injection

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.